Table 2 Baseline characteristics by NLR
| Â | Â | NLR | Â | |
|---|---|---|---|---|
Characteristic | No. of patients | <2.1 (n = 111) | ≥2.1 (n = 104) | P |
No. (%) | No. (%) | |||
Age (yr)a | 215 | 45.4 ± 9.3 | 47.5 ± 10.2 | NS |
cTb | 215 | Â | Â | <0.05 |
 1 |  | 2 (1.8) | 1 (1.0) |  |
 2 |  | 66 (59.5) | 42 (40.4) |  |
 3 |  | 36 (32.4) | 48 (46.2) |  |
 4 |  | 7 (6.3) | 13 (12.5) |  |
cNb | 215 | Â | Â | NS |
  0 |  | 25 (22.5) | 21 (20.2) |  |
  1 |  | 61 (55.0) | 47 (45.2) |  |
  2 |  | 18 (16.2) | 25 (24.0) |  |
  3 |  | 7 (6.3) | 11 (10.6) |  |
cTNMb | 215 | Â | Â | <0.05 |
  0 |  | 0(0.0) | 0(0.0) |  |
  1 |  | 0(0.0) | 0(0.0) |  |
  2 |  | 67 (60.4) | 41 (39.4) |  |
  3 |  | 44 (39.6) | 63 (60.6) |  |
HG | 215 | Â | Â | NS |
  1 |  | 36 (32.4) | 32 (30.8) |  |
  2 |  | 51 (45.9) | 42 (40.4) |  |
  3 |  | 24 (21.6) | 30 (28.8) |  |
ER | 215 | Â | Â | NS |
  - |  | 27 (24.3) | 38 (36.5) |  |
  + |  | 84 (75.7) | 66 (63.5) |  |
PR | 215 | Â | Â | NS |
  - |  | 39 (35.1) | 34 (32.7) |  |
  + |  | 72 (64.9) | 70 (67.3) |  |
HER2 | 215 | Â | Â | NS |
  - |  | 68 (61.3) | 70 (67.3) |  |
  + |  | 43 (38.7) | 34 (32.7) |  |
ER+ and/or PR+ | 174 | 93 (83.8) | 81 (77.9) | NS |
ER− PR− | 41 | 18 (16.2) | 23 (22.1) |  |
Molecular subtype | 215 | Â | Â | NS |
  Luminal A |  | 62 (55.9) | 58 (55.8) |  |
  Luminal B |  | 30 (27.0) | 22 (21.2) |  |
  HER2-enriched |  | 12 (10.8) | 13 (12.5) |  |
  Triple-negative |  | 7 (6.3) | 11 (10.6) |  |
CRP (before NAC) | 215 | 1.5 (0.5, 4.8) | 2.9 (0.9, 6.7) | <0.05 |
Relapse (local and distant) | Â | Â | Â | <0.05 |
  No | 176 | 98 (88.3) | 78 (75.0) |  |
  Yes | 39 | 13 (11.7) | 26 (25.0) |  |
Death | Â | Â | Â | <0.05 |
  No | 183 | 102 (91.9) | 81 (77.9) |  |
  Yes | 32 | 9 (8.1) | 23 (22.1) |  |